Circulating Tumor HPV DNA Complements PET-CT in Guiding Management after Radiotherapy in HPV-Related Squamous Cell Carcinoma of the Head and Neck.

Circulating Tumor HPV DNA Complements PET-CT in Guiding Management after Radiotherapy in HPV-Related Squamous Cell Carcinoma of the Head and Neck.:

Related Articles

Circulating Tumor HPV DNA Complements PET-CT in Guiding Management after Radiotherapy in HPV-Related Squamous Cell Carcinoma of the Head and Neck.

Int J Cancer. 2020 Sep 07;:

Authors: Tanaka H, Takemoto N, Horie M, Takai E, Fukusumi T, Suzuki M, Eguchi H, Komukai S, Tatsumi M, Isohashi F, Ogawa K, Yachida S, Inohara H

Abstract

Positron emission tomography and computed tomography (PET-CT) is widely used to assess the response to radiotherapy. However, the ability of PET-CT to predict treatment failure in human papillomavirus (HPV)-related squamous cell carcinoma of the head and neck (HNSCC) is unsatisfactory. We quantified circulating tumor HPV type16 DNA (ctHPV16DNA) using optimized droplet digital PCR (ddPCR) in 35 patients with HPV16-related HNSCC, who received radiotherapy with or without chemotherapy, and prospectively correlated ctHPV16DNA and metabolic response with treatment failure. After a median follow-up of 21 months, ctHPV16DNA and PET-CT had similar negative predictive values (89.7% vs 84.0%), whereas the positive predictive value was much higher in ctHPV16DNA than in PET-CT (100% vs 50.0%). Notably, six patients who had detectable post-treatment ctHPV16DNA all had treatment failure irrespective of metabolic response, whereas none of five patients who had partial metabolic response without detectable post-treatment ctHPV16DNA had treatment failure. The risk of treatment failure was high in patients who had incomplete metabolic response with detectable post-treatment ctHPV16DNA (hazard ratio [HR], 138.8; 95% confidence interval [CI], 15.5-3366.4; P < 0.0001) and intermediate in patients who had discordant results between metabolic response and post-treatment ctHPV16DNA (HR,4.7; 95% CI, 0.8-36.2, P = 0.09) as compared with patients who had complete metabolic response without detectable post-treatment ctHPV16DNA. One-year event-free survival rates of each risk group were 0%, 88% (95% CI, 46-98), and 95% (95% CI, 72-99), respectively (P < 0.0001). In conclusion, post-treatment ctHPV16DNA complements PET-CT and helps guide decisions managing patients with HPV16-related HNSCC after radiotherapy.



PMID: 32895945 [PubMed - as supplied by publisher]